GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » EPS (Diluted)

Extrawell Pharmaceutical Holdings (HKSE:00858) EPS (Diluted) : HK$-0.07 (TTM As of Sep. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings EPS (Diluted)?

Extrawell Pharmaceutical Holdings's Earnings per Share (Diluted) for the six months ended in Sep. 2023 was HK$-0.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was HK$-0.07.

Extrawell Pharmaceutical Holdings's EPS (Basic) for the six months ended in Sep. 2023 was HK$-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was HK$-0.07.

Extrawell Pharmaceutical Holdings's EPS without NRI for the six months ended in Sep. 2023 was HK$-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was HK$-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Extrawell Pharmaceutical Holdings's highest 3-Year average EPS without NRI Growth Rate was 58.70% per year. The lowest was -54.30% per year. And the median was -0.20% per year.


Extrawell Pharmaceutical Holdings EPS (Diluted) Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings EPS (Diluted) Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 -0.05 0.04 0.04

Extrawell Pharmaceutical Holdings Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 0.02 0.03 -0.10

Competitive Comparison of Extrawell Pharmaceutical Holdings's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's PE Ratio falls into.



Extrawell Pharmaceutical Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Extrawell Pharmaceutical Holdings's Diluted EPS for the fiscal year that ended in Mar. 2023 is calculated as

Diluted EPS (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(129.265-0)/3290.000
=0.04

Extrawell Pharmaceutical Holdings's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-237.725-0)/2390.000
=-0.10

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Extrawell Pharmaceutical Holdings  (HKSE:00858) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Extrawell Pharmaceutical Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Traded in Other Exchanges
N/A
Address
979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Executives
Mao Yumin 2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited 2201 Interest of corporation controlled by you
Ease Gold Investments Limited 2201 Interest of corporation controlled by you
Jnj Investments Ltd 2201 Interest of corporation controlled by you
United Gene Group Ltd 2201 Interest of corporation controlled by you
United Gene Holdings Limited 2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited 2101 Beneficial owner
Xie Yi 2201 Interest of corporation controlled by you
Huang Zhenping 2101 Beneficial owner
United Gene Industry Group Limited 2101 Beneficial owner
Chen Xuhua 2202 Interest of your spouse
Cheng Yong 2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines